Advertisement

Archives of Dermatological Research

, Volume 311, Issue 1, pp 29–36 | Cite as

A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata

  • Daniela Mikhaylov
  • Ana Pavel
  • Christopher Yao
  • Grace Kimmel
  • John Nia
  • Peter Hashim
  • Anjali S. Vekaria
  • Mark Taliercio
  • Giselle Singer
  • Rachel Karalekas
  • Danielle Baum
  • Yasaman Mansouri
  • Mark G. Lebwohl
  • Emma Guttman-YasskyEmail author
Original Paper

Abstract

Alopecia areata (AA) is a common autoimmune disease that results in non-scarring hair loss. AA pathogenesis is thought to involve multiple inflammatory cytokines. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that reduces pro-inflammatory cytokine production. Recent studies demonstrate upregulation of PDE4 in human scalp lesions of AA patients and hair regrowth in a humanized AA mouse model upon apremilast treatment, suggesting a possible potential of apremilast in AA. To assess the efficacy and safety of apremilast in AA, we conducted a double-blind, placebo-controlled single-center pilot study in 30 moderate-to-severe AA patients (≥ 50% scalp involvement) that were randomized 2:1 to receive apremilast (n = 20) or placebo (n = 10) orally for 24 weeks. The primary endpoint was the percentage of patients achieving 50% reduction in severity of alopecia tool (SALT) score (SALT50) at 24 weeks compared to baseline, and the secondary endpoints included the percent change in SALT score at weeks 24 and 48. Eight patients in the apremilast arm withdrew prior to week 24 along with two patients in the placebo group, mostly due to lack of efficacy and adverse events. At 24 weeks, only 1 of 12 apremilast-treated subjects achieved SALT50, and similarly 1 of 8 placebo-treated subjects achieved SALT50. The difference between the mean percent improvement in SALT score at week 24 compared to baseline of the two study arms was not statistically significant (p = 0.38). The lack of treatment response in most of our patients argues against a pathogenic role for PDE4 specifically in moderate-to-severe AA, but targeting this pathway may still be of value in patients with mild AA as there is less of an inflammatory burden in this population. However, future larger studies may be needed to conclude apremilast’s lack of efficacy in moderate-to-severe AA.

Keywords

Alopecia areata Apremilast PDE4 inhibitor Placebo-controlled trial Moderate-to-severe AA 

Abbreviations

AA

Alopecia areata

SALT

Severity of alopecia tool

Notes

Funding

This study was funded by Celgene (Grant number AP-CL-ALOP-PI-005776).

Compliance with ethical standards

Conflict of interest

Daniela Mikhaylov, Ana Pavel, Christopher Yao, Giselle Singer, Mark Taliercio, Rachel Karalekas, John Nia, Peter Hashim, Grace Kimmel, Danielle Baum, Yasaman Mansouri, and Anjali S. Vekaria have no conflicts of interest to disclose. Dr. Emma Guttman-Yassky is a board member of Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Celsus, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae and Leo Pharma; has received consultancy fees from Regeneron, Sanofi, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, LEO Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe and Eli Lilly; and has received research support from Janssen, Regeneron, Celgene, BMS, Novartis, Merck, LEO Pharma and Dermira. Dr. Mark Lebwohl is an employee of Mount Sinai, which receives research funds from Amgen, Anacor Pharmaceuticals Inc, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Janssen Biotech, Kadmon Corporation, LEO Pharmaceuticals, MedImmune, Novartis Pharmaceuticals Corporation, Pfizer, Sun Pharmaceuticals Industries Ltd, and Valeant Pharmaceuticals. The authors did not receive any form of compensation, either directly or indirectly, from any company or agency related to the development, authorship, or publication of this article.

Supplementary material

403_2018_1876_MOESM1_ESM.docx (26 kb)
Supplementary material 1 (DOCX 26 KB)

References

  1. 1.
    Acikgoz G, Caliskan E, Tunca M, Yeniay Y, Akar A (2014) The effect of oral cyclosporine in the treatment of severe alopecia areata. Cutan Ocul Toxicol 33:247–252.  https://doi.org/10.3109/15569527.2013.839997 CrossRefGoogle Scholar
  2. 2.
    Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J (2010) Alopecia areata update: part II. Treatment. J Am Acad Dermatol 62:191–202.  https://doi.org/10.1016/j.jaad.2009.10.031 quiz 203 – 194.CrossRefGoogle Scholar
  3. 3.
    Bakry OA, El Shazly RM, Basha MA, Mostafa H (2014) Total serum immunoglobulin E in patients with alopecia areata. Indian dermatology online journal 5:122–127.  https://doi.org/10.4103/2229-5178.131076 CrossRefGoogle Scholar
  4. 4.
    Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R (2017) Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol 77:167–170.  https://doi.org/10.1016/j.jaad.2017.03.024 CrossRefGoogle Scholar
  5. 5.
    Chiang K, Atanaskova Mesinkovska N, Amoretti A, Piliang MP, Kyei A, Bergfeld WF (2014) Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J Am Acad Dermatol 71:595–597.  https://doi.org/10.1016/j.jaad.2014.04.036 CrossRefGoogle Scholar
  6. 6.
    Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Investig Dermatol 134:2988–2990.  https://doi.org/10.1038/jid.2014.260 CrossRefGoogle Scholar
  7. 7.
    Czarnowicki T, He HY, Wen HC, Hashim PW, Nia JK, Malik K, Estrada Y, Kimmel GW, Taliercio M, Krueger JG, Guttman-Yassky E (2018) Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin-homing and systemic T-cell populations. Allergy 73:713–723.  https://doi.org/10.1111/all.13346 CrossRefGoogle Scholar
  8. 8.
    de Hollanda TR, Sodre CT, Brasil MA, Ramos ESM (2014) Quality of life in alopecia areata: a case-control study. Int J Trichol 6:8–12.  https://doi.org/10.4103/0974-7753.136748 CrossRefGoogle Scholar
  9. 9.
    Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J (2008) Interventions for alopecia areata. Cochrane Database Syst Rev Cd004413.  https://doi.org/10.1002/14651858.CD004413.pub2 Google Scholar
  10. 10.
    Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 75:1065–1073.  https://doi.org/10.1136/annrheumdis-2015-207963 CrossRefGoogle Scholar
  11. 11.
    Farshi S, Mansouri P, Safar F, Khiabanloo SR (2010) Could azathioprine be considered as a therapeutic alternative in the treatment of alopecia areata? A pilot study. Int J Dermatol 49:1188–1193.  https://doi.org/10.1111/j.1365-4632.2010.04576.x CrossRefGoogle Scholar
  12. 12.
    Gade VKV, Mony A, Munisamy M, Chandrashekar L, Rajappa M (2018) An investigation of vitamin D status in alopecia areata. Clin Exp Med.  https://doi.org/10.1007/s10238-018-0511-8 Google Scholar
  13. 13.
    Gilhar A, Kalish RS (2006) Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev 5:64–69.  https://doi.org/10.1016/j.autrev.2005.07.001 CrossRefGoogle Scholar
  14. 14.
    Giordano CN, Sinha AA (2013) Cytokine pathways and interactions in alopecia areata. Eur J Dermatol EJD 23:308–318.  https://doi.org/10.1684/ejd.2013.2042 Google Scholar
  15. 15.
    Guttman-Yassky E, Ungar B, Noda S, Suprun M, Shroff A, Dutt R, Khattri S, Min M, Mansouri Y, Zheng X, Estrada YD, Singer GK, Suarez-Farinas M, Krueger JG, Lebwohl MG (2016) Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. J Allergy Clin Immunol 137:301–304.  https://doi.org/10.1016/j.jaci.2015.11.001 CrossRefGoogle Scholar
  16. 16.
    Hordinsky MK (2015) Current treatments for alopecia areata. J Investig Dermatol Symp Proc 17:44–46.  https://doi.org/10.1038/jidsymp.2015.41 CrossRefGoogle Scholar
  17. 17.
    Huang KP, Mullangi S, Guo Y, Qureshi AA (2013) Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol 149:789–794.  https://doi.org/10.1001/jamadermatol.2013.3049 CrossRefGoogle Scholar
  18. 18.
    Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach-Mansky R, Christiano AM, Clynes R, Zlotogorski A (2015) Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine 2:351–355.  https://doi.org/10.1016/j.ebiom.2015.02.015 CrossRefGoogle Scholar
  19. 19.
    Keren A, Shemer A, Ullmann Y, Paus R, Gilhar A (2015) The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. J Dermatol Sci 77:74–76.  https://doi.org/10.1016/j.jdermsci.2014.11.009 CrossRefGoogle Scholar
  20. 20.
    Kurosawa M, Nakagawa S, Mizuashi M, Sasaki Y, Kawamura M, Saito M, Aiba S (2006) A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology 212:361–365.  https://doi.org/10.1159/000092287 CrossRefGoogle Scholar
  21. 21.
    Langley A, Beecker J (2018) Management of common side effects of apremilast. J Cutan Med Surg 22:415–421.  https://doi.org/10.1177/1203475417748886 CrossRefGoogle Scholar
  22. 22.
    Liu LY, Craiglow BG, Dai F, King BA (2017) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 76:22–28.  https://doi.org/10.1016/j.jaad.2016.09.007 CrossRefGoogle Scholar
  23. 23.
    Liu LY, King BA (2017) Lack of efficacy of apremilast in 9 patients with severe alopecia areata. J Am Acad Dermatol 77:773–774.  https://doi.org/10.1016/j.jaad.2017.05.034 CrossRefGoogle Scholar
  24. 24.
    MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG (2003) Guidelines for the management of alopecia areata. Br J Dermatol 149:692–699CrossRefGoogle Scholar
  25. 25.
    Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R (2016) Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight 1:e89790.  https://doi.org/10.1172/jci.insight.89790 CrossRefGoogle Scholar
  26. 26.
    O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A (2013) Janus kinase Inhibitors in autoimmune diseases. Ann Rheum Dis 72:ii111–ii115.  https://doi.org/10.1136/annrheumdis-2012-202576 CrossRefGoogle Scholar
  27. 27.
    Otberg N (2011) Systemic treatment for alopecia areata. Dermatol Ther 24:320–325.  https://doi.org/10.1111/j.1529-8019.2011.01420.x CrossRefGoogle Scholar
  28. 28.
    Park KY, Jang WS, Son IP, Choi SY, Lee MY, Kim BJ, Kim MN, Ro BI (2013) Combination therapy with cyclosporine and psoralen plus ultraviolet a in the patients with severe alopecia areata: a retrospective study with a self-controlled design. Ann Dermatol 25:12–16.  https://doi.org/10.5021/ad.2013.25.1.12 CrossRefGoogle Scholar
  29. 29.
    Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG (2018) Mechanisms underlying the clinical effects of apremilast for psoriasis. J Drugs Dermatol JDD 17:835–840Google Scholar
  30. 30.
    Renert-Yuval Y, Guttman-Yassky E (2016) A novel therapeutic paradigm for patients with extensive alopecia areata. Expert Opin Biol Ther 16:1005–1014.  https://doi.org/10.1080/14712598.2016.1188076 CrossRefGoogle Scholar
  31. 31.
    Renert-Yuval Y, Guttman-Yassky E (2017) The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther 34:1594–1609.  https://doi.org/10.1007/s12325-017-0542-7 CrossRefGoogle Scholar
  32. 32.
    Samrao A, Berry TM, Goreshi R, Simpson EL (2012) A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 148:890–897.  https://doi.org/10.1001/archdermatol.2012.812 CrossRefGoogle Scholar
  33. 33.
    Schafer P (2012) Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 83:1583–1590.  https://doi.org/10.1016/j.bcp.2012.01.001 CrossRefGoogle Scholar
  34. 34.
    Scheinberg M, Ferreira S (2016) Reversal of alopecia universalis by tofacitinib: a case report. Ann Intern Med 165:750–751.  https://doi.org/10.7326/L16-0125 CrossRefGoogle Scholar
  35. 35.
    Suarez-Farinas M, Ungar B, Noda S, Shroff A, Mansouri Y, Fuentes-Duculan J, Czernik A, Zheng X, Estrada YD, Xu H, Peng X, Shemer A, Krueger JG, Lebwohl MG, Guttman-Yassky E (2015) Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol 136:1277–1287.  https://doi.org/10.1016/j.jaci.2015.06.032 CrossRefGoogle Scholar
  36. 36.
    Tembhre MK, Sharma VK (2013) T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata. Br J Dermatol 169:543–548.  https://doi.org/10.1111/bjd.12396 CrossRefGoogle Scholar
  37. 37.
    Tosti A, Bellavista S, Iorizzo M (2006) Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol 55:438–441.  https://doi.org/10.1016/j.jaad.2006.05.008 CrossRefGoogle Scholar
  38. 38.
    Waldmann TA (2013) The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J Investig Dermatol Symp Proc 16:S28–S30.  https://doi.org/10.1038/jidsymp.2013.8 CrossRefGoogle Scholar
  39. 39.
    Wang ECE, Christiano AM (2017) The changing landscape of alopecia areata: the translational landscape. Adv Ther 34:1586–1593.  https://doi.org/10.1007/s12325-017-0540-9 CrossRefGoogle Scholar
  40. 40.
    Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20:1043–1049.  https://doi.org/10.1038/nm.3645 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Daniela Mikhaylov
    • 1
  • Ana Pavel
    • 1
  • Christopher Yao
    • 1
  • Grace Kimmel
    • 1
  • John Nia
    • 1
  • Peter Hashim
    • 1
  • Anjali S. Vekaria
    • 1
  • Mark Taliercio
    • 1
  • Giselle Singer
    • 1
  • Rachel Karalekas
    • 1
  • Danielle Baum
    • 1
  • Yasaman Mansouri
    • 1
  • Mark G. Lebwohl
    • 1
  • Emma Guttman-Yassky
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of DermatologyIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.Department of Dermatology and the Immunology InstituteIcahn School of Medicine at Mount SinaiNew YorkUSA
  3. 3.Laboratory for Investigative DermatologyRockefeller UniversityNew YorkUSA

Personalised recommendations